产品名称：Stemgent/Recombinant Human Activin A/03-0001/5 μg

产品编号：03-0001

市场价：¥0.00

场地：美国(厂家直采)

产品分类：蛋白类>重组蛋白>细胞因子>

联系QQ：1570468124

电话号码：4000-520-616

邮箱： info@ebiomall.com

美元价：待定

品牌： Stemgent

公司：Stemgent, Inc

公司分类：

商品介绍

ProductOverview

StemfactorActivinA isacrystallography-gradepreparationprovidingthehighestpurityavailable.ActivinAisbi-modalinactionhavingbeenshowntomaintainpluripotencyofstemcellsandpromotedifferentiation^1,2,3,4.MaturerecombinanthumanActivinAisa~25kDadisulfide-linkedhomodimeroftwo116aminoacidresidueβAsubunits.

Stemgentconvenientlyprovides all thecomponents comprising the5i/L/Amediasupplmentnecessarytosupportnaivepluripotentstemcellapplications.

5i(inhibitors):

Stemolecule™PD0325901(04-0006),
Stemolecule™Y27632(04-0012),
Stemolecule™WH-4-023(04-0079),
Stemolecule™SB590885(04-0080),
Stemolecule™IM-12(04-0081)oralternatively,
Stemolecule™CHIR99021(04-0004)

L:Stemfactor™LIF,HumanRecombinant(03-0016),and

A:Stemfactor™ActivinA,HumanRecombinant(03-0001)

ProductSpecifications

Size

5μg

Source

E.Coli

Formulation

Lyophilizedfrom20%acetonitrile

AminoAcidSequence

GLECDGKVNICCKKQFFVSFKDIGWNDWIIAPSGYHANYCEGECPSHIAGTSGSSLSFHSTVINHYRMRGHSPFANLKSCCVPTKLRPMSMLYYDDGQNIIKKDIQNMIVEECGCS

UniprotAccessionNumber

P08476,residues311-426

Purity

Greaterthan98%bySDS-PAGEanalysis

EndotoxinLevel

Lessthan 1.0EU/μgofActivinAasdeterminedbytheLALmethod.

BIOLOGicActivity

TheED₅₀islessthan 6ng/mlasdeterminedbyitsABIlitytoinhibittheproliferationofmouseMPC-11cells.

StorageandStability

ActivinAisshippedatroomtemperature.LyophilizedActivinAisstableforupto6monthsfromdateofreceiptwhenstoredat-20°Cto-80°C. ReconstitutedActivinA,atconcentrationsgreaterthan0.1mg/ml,isstableforupto3monthswhenstoredat-20°Candfor1yearwhenstoredat-80°C

Reconstitution

CentrifugebrieflyandreconstituteActivinAin10mMHClbeforedilutionincellculturemedium.Avoidfreeze-thawcyclesasitcanresultinlossofactivity.

SpecificationSheets

03-0001SpecificationsSheet

SafetyDataSheets

03-0001SafetyDataSheet

References

Beattie,G.M.,Lopez,A.D.,Bucay,N.,Hinton,A.,Firpo,M.T.,King,C.C.,andHayek,A.(2005)ActivinAmaintainspluripotencyofhumanembryonicstemcellsintheabsenceoffeederlayers.StemCells23:489-495.
Vallier,L.,Alexander,M.,andPedersen,R.A.(2005)Activin/NodalandFGFpathwayscorporatetomaintainpluripotencyofhumanembryonicstemcells.J.CellSci.118:4495-4509.
Sulzbacher,S.,Schroeder,I.S.,Truong,T.T.,andWobus,A.M.(2009)ActivinA-induceddifferentiationofembryonicstemcellsintoendodermandpancreaticProgenitors-theinfluenceofdifferentiationfactorsandcultureconditions.StemCellRev.5:159-173.
Valdimarsdottir,G.,andMummery,C.(2005)FunctionsoftheTGFbetasuperfamilyinhumanembryoniccells.APMIS113:773-789.

AdditionalPublications

Villa-DiazLG;KimJK;LaperleA;PalecekSP;KresbachPH."Inhibitionoffocaladhesionkinasesignalingbyintegrina6b1supportshumanstemcellself-renewal."StemCellsdoi:10.1002/stem.2349(2016)
ZhuS;RussHA;WangX;ZhangM;MaT;XuT;TangS;HebrokM;DengS."Humanpancreaticbeta-likecellsconvertedfromfibroblasts."NatureCommun7:10080(2016)
SaxenaS;RonnRE;GuibentifC;MoraghebaR;WoodsN-B."CyclicAMPsignalingthroughEpacaxismodulateshumanhemogenicendotheliumandenhanceshematopoeiticcellgeneration."StemCellRepdoi:10.1016/j.stemcr.2016.03.006(2016)
Mora-CastillaS;ToC;VaezeslamiS;MoreyR;SrinivasanS;DumdieJN;Cook-AndersenH;JenkinsJ;LaurentLC."Miniaturizationtechnologiesforefficientsingle-celllibrarypreparationfornext-generationsequencing."JLabAutomation2016:1(2016)
QianX."Definingthemechanismbywhichsyntheticpolymersurfacessupporthumanpluripotentstemcellself-renewal."PhDThesis,UniversityofMichigan(2015)
Villa-DiazLG;KimJK;LahannJ;KresbachPH."Derivationandlong-termcultureoftransfene-freehumaninducedpluripotentstemcellsonsyntheticsubstates."StemCellsTransMed3:1410(2014)
Bukong,T.N.,Lo,T.,Szabo,G.,andDolganiuc,A.(2012)Noveldevelopmentalbiology-basedprotocolofembryonicstemcelldifferentiationtomorphologicallysoundandfunctionalyetimmaturehepatocytes.LiverInt.doi:10.1111/j.1478-3231.2011.02743.x.[Epubaheadofprint]
Kunisada,Y.,Tsubooka-Yamazoe,N.,Shoji,M.,andHosoya,M.(2012)Smallmoleculesinduceefficientdifferentiationintoinsulin-producingcellsfromhumaninducedpluripotentstemcells.StemCellRes8:274-284.
McCracken,K.W.,Howell,J.C.,Wells,J.M.,andSpence,J.R.(2011)Generatinghumanintestinaltissuefrompluripotentstemcellsinvitro.NatProtoc6:1920-1928.

品牌介绍

Stemgent mRNA体细胞重编程系统

产品特点

1.快速 Fast

Stemgent® MicroRNA-Enhanced mRNA Reprogramming System只需2周即可将靶细胞重编程为iPS细胞，与仙台病毒（Sendai Virus）、非整合型DNA载体（Episomal DNA Vectors）等传统iPS重编程方法相比，缩短实验周期超过50%以上（Figure. 1）。

Figure 1. Stemgent® mRNA重编程系统、仙台病毒依赖的重编程系统以及游离型DNA载体依赖的重编程系统重编程时程比较。

简便 Easy

与病毒、DNA载体依赖的iPS重编程手段不同，使用Stemgent® MicroRNA-Enhanced mRNA Reprogramming System对靶细胞进行重编程，生成的iPS细胞无需进行复杂耗时的下游筛选程序，只需简简单单6个步骤，即可轻松构建iPS细胞系。

	Description	Day
Step 1	Material Preparation	Prior to starting
Step 2	Plate Cells	0
Step 3	Transfect Cells	1 to 12
Step 4	Identify Cells	13-14
Step 5	Pick and Passage iPS Cell Colonies	15-16
Step 6	Maintain iPS Cell Cultures	16+

注：因所用细胞类型及实验条件不同，上述时间轴可能略有不同，仅供参考。

Figure 2. Stemgent® MicroRNA-Enhanced mRNA Reprogramming System重编程过程时间表、显微镜下观察到的重编程过程中靶细胞形态变化。第12天，形成的iPS克隆表达多能型Marker TRA-1-81。

高效 Efficient

病毒、DNA载体等依赖的iPS重编程技术，其重编程效率介于0.00001%到1%之间不等，而Stemgent® MicroRNA-Enhanced mRNA Reprogramming System的重编程效率远远大于1%，极大地提高了iPS克隆的产出率。

表1. 不同类型iPS重编程手段效率比较

Reprogramming Method	Efficiency	Integrating	Screening
RNA	>1%	No	No
仙台病毒（Sendai virus）	0.01-1%	No	Yes
DNA载体（Episomal/Minicircle）	0.00%	Possible	Yes
慢病毒（Lentivirus）	0.001-0.01%	Yes	Yes
腺病毒（Adenovirus）	0.0001-0.001%	Possible	Yes
Protein	0.00%	No	No

安全 Safe

某些iPS研究领域，例如iPS临床研究、治疗应用等，对iPS细胞的安全性提出了极高的要求。使用Stemgent® MicroRNA-Enhanced mRNA Reprogramming System重编程靶细胞，无需担心构建的iPS细胞系可能含有病毒载体残留，亦无需担心无关的基因整合进宿主基因组，是目前适用于临床研究及治疗的最理想选择。

而以仙台病毒（Sendai Virus）为载体的iPS重编程手段，其病毒基因组虽然不会整合进宿主染色体，仙台病毒本身也不具备复制能力，但是为了构建真正意义上的virus-free的iPS细胞系，通常需要经过一个10-20代、耗时费力的筛选过程，以确保最终得到的iPS细胞系无病毒载体残留。以慢病毒（Lentivirus）体的iPS重编程手段，病毒基因组能够永久整合进宿主基因组，会给后续的iPS细胞分析带来干扰。